Skip to main content

Enzyme Replacement Therapy Deal Benchmarks

Median Upfront
$425M
Range: $207M - $645M
Total Deal Value
$2.3B
Range: $1.4B - $3.3B
Royalty Rate
7.8% - 15.6%
Tiered up to 19.6%
Dev Milestones
$419M
Range: $252M - $586M
Model Your Deal

Market Analysis

Enzyme replacement therapies remain the backbone of lysosomal storage disorder treatment, generating $8B+ annually across Fabry, Gaucher, Pompe, and MPS indications. Phase 2 ERT deals carry a median total deal value of $2.3B, with upfront payments of $425M. The recurring revenue model (lifelong treatment at $200K-$500K per patient annually) and orphan drug protections drive strong licensing economics.

ERT deal structures reflect the predictable revenue model of chronic therapy. Development milestones average $419M, with regulatory milestones of $476M and commercial milestones of $1.0B. The 18/82 upfront/milestone split balances clinical risk with the established commercial precedent in the enzyme replacement space.

Royalty rates for ERT licensing range from 7.8% to 15.6%, reflecting the high per-patient revenue and limited biosimilar competition. Next-generation ERTs with improved half-life, tissue penetration, or oral bioavailability command premium terms. The competitive threat from gene therapy approaches is increasingly factored into ERT deal valuations, with licensees seeking assets that offer differentiated patient convenience or efficacy advantages.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are typical deal terms for ERT licensing?
Phase 2 ERT deals average $425M upfront with $2.3B total deal value. The recurring revenue model ($200K-$500K per patient annually for life) provides predictable commercial economics that support strong deal valuations.
How do ERT deals compare to gene therapy deals in rare disease?
ERT deals typically feature lower total deal values than gene therapy but offer more predictable revenue streams. Gene therapies command higher upfronts due to curative one-time treatment potential, while ERTs generate recurring revenue over decades. Many licensees now seek both modalities for complementary portfolio positioning.
What drives premium valuations for ERT assets?
Key premium drivers include improved enzyme stability or half-life, novel formulations enabling subcutaneous or oral delivery, expanded tissue penetration (e.g., CNS-penetrant ERTs for neuropathic variants), and activity in underserved patient populations. Next-generation ERTs with demonstrated superiority over first-generation products command 20-30% premiums.
What is the biosimilar risk for ERT deals?
ERT biosimilar risk is moderate but growing. Complex manufacturing and limited patient populations have slowed biosimilar entry compared to oncology biologics. However, Fabry and Gaucher ERTs face increasing biosimilar competition, which is reflected in royalty term negotiations and lifecycle management provisions.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Rare Disease Overview

View

Gene Therapy Rare Disease Deals

View

Phase 2 Deal Benchmarks

View

Small Molecule Deals

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included